PE20070188A1 - Formulaciones de estrogenos conjugados y bazedoxifeno - Google Patents
Formulaciones de estrogenos conjugados y bazedoxifenoInfo
- Publication number
- PE20070188A1 PE20070188A1 PE2006000757A PE2006000757A PE20070188A1 PE 20070188 A1 PE20070188 A1 PE 20070188A1 PE 2006000757 A PE2006000757 A PE 2006000757A PE 2006000757 A PE2006000757 A PE 2006000757A PE 20070188 A1 PE20070188 A1 PE 20070188A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- pharmaceutical formulation
- formulation
- bazedoxifene
- formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940036507 conjugated estrogen and bazedoxifene Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 7
- 238000009472 formulation Methods 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 abstract 1
- 239000013522 chelant Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940035811 conjugated estrogen Drugs 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE TABLETA QUE COMPRENDE: A) UN NUCLEO QUE COMPRENDE ESTROGENOS CONJUGADOS EN UNA CANTIDAD DESDE 0.1-1,0 mg; B) UNA COBERTURA QUE COMPRENDE BAZEDOXIFENO DE BASE LIBRE EN UNA CANTIDAD DE 5-25 mg. EL NUCLEO COMPRENDE DESDE CERCA DE 45-80% POR PESO DE LA FORMULACION FARMACEUTICA Y LA COBERTURA CONSTA DE: 1) UN COMPONENTE DE RELLENO DE 6-12% POR PESO DE LA FORMULACION FARMACEUTICA; 2) UN AGLOMERANTE DE CERCA DE 6% DE LA FORMULACION FAMACEUTICA; 3) UN HUMECTANTE DE 0,01-3% POR PESO DE LA FORMULACION FARMACEUTICA; 4) UN ANTIOXIDANTE DE CERCA DE 0,5% POR PESO DE LA FORMULACION FARMACEUTICA; 5) ACETATO DE BAZEDOXIFENO, DE 2-6% POR PESO DE LA FORMULACION FARMACEUTICA; 6) UN QUELANTE DE 0-0,1% POR PESO DE LA FORMULACION FARMACEUTICA. DICHA FORMULACION ES UTIL EN LA TERAPIA DE REEMPLAZO HORMONAL PARA LA PREVENCION DE PERDIDA OSEA EN MUJERES POSTMENOPAUSICAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69488905P | 2005-06-29 | 2005-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070188A1 true PE20070188A1 (es) | 2007-03-16 |
Family
ID=37401610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000757A PE20070188A1 (es) | 2005-06-29 | 2006-06-28 | Formulaciones de estrogenos conjugados y bazedoxifeno |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20070003623A1 (es) |
| EP (1) | EP1898888A2 (es) |
| JP (1) | JP2008545012A (es) |
| KR (1) | KR20080031037A (es) |
| CN (1) | CN101252921A (es) |
| AR (1) | AR054806A1 (es) |
| AU (1) | AU2006263638A1 (es) |
| BR (1) | BRPI0612586A2 (es) |
| CA (1) | CA2613102A1 (es) |
| CR (1) | CR9597A (es) |
| EC (1) | ECSP078057A (es) |
| IL (1) | IL188223A0 (es) |
| NI (1) | NI200700331A (es) |
| NO (1) | NO20080002L (es) |
| PA (1) | PA8684501A1 (es) |
| PE (1) | PE20070188A1 (es) |
| RU (1) | RU2395286C2 (es) |
| TW (1) | TW200738283A (es) |
| WO (1) | WO2007002823A2 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0509381A (pt) * | 2004-04-08 | 2007-09-18 | Wyeth Corp | dispersão sólida, métodos de preparar a dispersão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência ou o excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal de tecidos endometrais, de tratar cáncer de mamas de um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, composição, forma de dosagem, e, uso de uma dispersão sólida |
| CA2670544A1 (en) * | 2006-11-29 | 2008-06-05 | Wyeth | Estrogen/ serm and estrogen/ progestin bi-layer tablets |
| MX2009007254A (es) * | 2007-01-12 | 2009-08-12 | Wyeth Corp | Composiciones de tableta en tableta. |
| PE20090100A1 (es) * | 2007-03-30 | 2009-02-26 | Wyeth Corp | Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas |
| ES2436841T3 (es) * | 2009-10-27 | 2014-01-07 | Wyeth Llc | Formulaciones de bazedoxifeno con antioxidantes |
| KR20130076818A (ko) * | 2010-04-20 | 2013-07-08 | 시플라 리미티드 | 약학 조성물 |
| WO2012016056A1 (en) * | 2010-07-29 | 2012-02-02 | Entropic Communications, Inc. | Method and apparatus for cross polarization and cross satellite interference cancellation |
| AU2012256501B2 (en) * | 2011-05-13 | 2017-04-06 | Eb Ip Hybritabs B.V. | Drug delivery system |
| CN104013630B (zh) * | 2014-05-23 | 2018-08-21 | 合肥九研医药科技开发有限公司 | 一种复方醋酸巴多昔芬雌激素组合物 |
| PE20180522A1 (es) | 2015-06-18 | 2018-03-14 | Mithra Pharmaceuticals S A | Unidad de dosificacion orodispersable que contiene un componente estetrol |
| KR102712911B1 (ko) | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| WO2018182205A1 (ko) * | 2017-03-30 | 2018-10-04 | 한미약품 주식회사 | 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물 |
| TWI801561B (zh) * | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| JOP20200260A1 (ar) * | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2565115A (en) * | 1948-10-28 | 1951-08-21 | Squibb & Sons Inc | Method of obtaining a conjugated estrogen preparation |
| US2720483A (en) * | 1951-02-21 | 1955-10-11 | Olin Mathieson | Method of obtaining a conjugatedestrogen preparation |
| US5210081A (en) * | 1992-02-26 | 1993-05-11 | American Home Products Corporation | Alkali metal 8,9-dehydroestrone sulfate esters |
| US5759577A (en) * | 1995-01-17 | 1998-06-02 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
| US5547948A (en) * | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
| US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| JP4790178B2 (ja) * | 1999-07-06 | 2011-10-12 | アンドルシェルシュ・インコーポレイテッド | 体重増加の処置方法および／または抑制方法 |
| AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| KR20050010886A (ko) * | 2002-06-13 | 2005-01-28 | 와이어쓰 | 바제독시펜 치료 방식 |
| CA2561010A1 (en) * | 2004-04-07 | 2005-10-27 | Wyeth | Crystalline polymorph of bazedoxifene acetate |
| GT200500080A (es) * | 2004-04-07 | 2005-10-31 | Polimorfo cristalino de acetato de bazedoxifeno | |
| BRPI0509381A (pt) * | 2004-04-08 | 2007-09-18 | Wyeth Corp | dispersão sólida, métodos de preparar a dispersão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência ou o excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal de tecidos endometrais, de tratar cáncer de mamas de um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, composição, forma de dosagem, e, uso de uma dispersão sólida |
| WO2005100315A1 (en) * | 2004-04-08 | 2005-10-27 | Wyeth | Bazedoxifene ascorbate as selective estrogen receptor modulator |
-
2006
- 2006-06-28 AU AU2006263638A patent/AU2006263638A1/en not_active Abandoned
- 2006-06-28 KR KR1020087002416A patent/KR20080031037A/ko not_active Ceased
- 2006-06-28 TW TW095123252A patent/TW200738283A/zh unknown
- 2006-06-28 BR BRPI0612586-7A patent/BRPI0612586A2/pt not_active IP Right Cessation
- 2006-06-28 JP JP2008520286A patent/JP2008545012A/ja not_active Withdrawn
- 2006-06-28 EP EP06785833A patent/EP1898888A2/en not_active Withdrawn
- 2006-06-28 RU RU2007148071/15A patent/RU2395286C2/ru not_active IP Right Cessation
- 2006-06-28 PE PE2006000757A patent/PE20070188A1/es not_active Application Discontinuation
- 2006-06-28 WO PCT/US2006/025348 patent/WO2007002823A2/en not_active Ceased
- 2006-06-28 AR ARP060102789A patent/AR054806A1/es unknown
- 2006-06-28 CA CA002613102A patent/CA2613102A1/en not_active Abandoned
- 2006-06-28 CN CNA2006800313156A patent/CN101252921A/zh active Pending
- 2006-06-28 US US11/478,400 patent/US20070003623A1/en not_active Abandoned
- 2006-06-29 PA PA20068684501A patent/PA8684501A1/es unknown
-
2007
- 2007-12-17 CR CR9597A patent/CR9597A/es not_active Application Discontinuation
- 2007-12-18 IL IL188223A patent/IL188223A0/en unknown
- 2007-12-18 NI NI200700331A patent/NI200700331A/es unknown
- 2007-12-27 EC EC2007008057A patent/ECSP078057A/es unknown
-
2008
- 2008-01-02 NO NO20080002A patent/NO20080002L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008545012A (ja) | 2008-12-11 |
| BRPI0612586A2 (pt) | 2010-11-23 |
| CR9597A (es) | 2008-03-06 |
| CN101252921A (zh) | 2008-08-27 |
| NI200700331A (es) | 2009-02-16 |
| WO2007002823A3 (en) | 2007-08-09 |
| EP1898888A2 (en) | 2008-03-19 |
| RU2395286C2 (ru) | 2010-07-27 |
| RU2007148071A (ru) | 2009-08-10 |
| PA8684501A1 (es) | 2007-01-17 |
| US20070003623A1 (en) | 2007-01-04 |
| ECSP078057A (es) | 2008-01-23 |
| TW200738283A (en) | 2007-10-16 |
| WO2007002823A2 (en) | 2007-01-04 |
| AU2006263638A1 (en) | 2007-01-04 |
| AR054806A1 (es) | 2007-07-18 |
| CA2613102A1 (en) | 2007-01-04 |
| NO20080002L (no) | 2008-03-12 |
| KR20080031037A (ko) | 2008-04-07 |
| IL188223A0 (en) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070188A1 (es) | Formulaciones de estrogenos conjugados y bazedoxifeno | |
| MY169516A (en) | Pharmaceutical composition containing a tetrahydrofolic acid | |
| PE20070208A1 (es) | Anticoncepcion oral con trimegestona | |
| CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
| PT2038290E (pt) | Moduladores de receptor do tipo toll 7 | |
| EA200900491A1 (ru) | Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола | |
| WO2007048219A3 (en) | Sustained drug release composition | |
| AR057060A1 (es) | Composiciones de tanaproget que contienen etinil estradiol | |
| PE20070329A1 (es) | Composiciones con estrogenos y metodos terapeuticos para su uso | |
| NZ605176A (en) | Pharmaceutical composition comprising drospirenone and contraceptive kit | |
| UA96302C2 (en) | Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid | |
| PE20070327A1 (es) | Composicion que comprende una progestina y un estrogeno | |
| MX2009002180A (es) | Metodo de inhibicion de la depresion respiratoria mediante el uso de moduladores alostericos positivos del receptor ampa. | |
| GT200800107A (es) | Formulaciones orales que comprenden tigeciclina | |
| PE20060275A1 (es) | Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual | |
| UA87841C2 (ru) | Композиция, которая содержит амброксол, для местного применения | |
| CR10289A (es) | "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional) | |
| MX2010006259A (es) | Piperazinas como agentes antiobesidad. | |
| MX2010001243A (es) | Composicion anti-inflamatoria. | |
| PE20060318A1 (es) | Forma de administracion para la contracepcion hormonal | |
| PT1768985E (pt) | Derivados de pirimido-benzimidazole e sua utilização como agonistas ou antagonistas dos receptores das melanocortinas | |
| AR065971A1 (es) | Nuevo regimen de drosperinona/17beta-estradiol, producto farmaceutica combinado y conjunto de elementos (kit) para su aplicacion | |
| BRPI0509067A (pt) | formulações de matriz oral que compreendem licarbazepina | |
| PE20060368A1 (es) | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona | |
| EA201000097A1 (ru) | 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |